Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

4.525 +0.355 (+8.51%)
Streaming Delayed Price Updated: 1:20 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CAMP4 Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder 
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints Michael MacLean to its Board of Directors
Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder 
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
Via The Motley Fool
News headline image
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies. 
Via The Motley Fool
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗
Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗
One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next. 
Via The Motley Fool
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
3 Healthcare Companies Insiders Are Buying ↗
Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years. 
Via MarketBeat
Topics Initial Public Offering
News headline image
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.